Nov 5, 6:12 AM ET
Ingredion reported third quarter 2026 diluted EPS of $2.23, down from $2.61 a year earlier, and net sales of $1.79 billion, down 1%. Reported operating income fell 19% to $201 million. The company lowered its full-year 2026 outlook, citing a slower recovery at its Argo facility, higher input costs and softer demand, which points to lower earnings for shareholders.
- Q3 2026 reported diluted EPS was $2.23 versus $2.61 in Q3 2025; adjusted diluted EPS was $2.28 versus $2.75.
- Full-year 2026 reported diluted EPS guidance is now $8.04 to $8.49; adjusted diluted EPS guidance is now $9.25 to $9.70.
- Food & Industrial Ingredients – U.S./CAN operating income is now expected to be down 35% to 40% for 2026, driven by operating costs at Argo.
- Full-year 2026 cash from operations is now expected to be $650 million to $750 million.
Read the filing on SEC.gov ↗
Aug 4, 6:09 AM ET
Ingredion reported second quarter 2026 net sales of $1.85 billion, up 1% from a year earlier, while reported diluted EPS fell 40% to $1.78 and operating income fell 31% to $188 million. The company reaffirmed its amended full-year 2026 EPS guidance, which now reflects the sale of a majority stake in its Pakistan business, and said Tate & Lyle shareholders approved its all-cash offer on July 28, 2026.
- Q2 2026 reported diluted EPS was $1.78 versus $2.99 in Q2 2025; adjusted EPS was $2.82 versus $2.87.
- Full-year 2026 reported EPS guidance of $9.15 to $9.75 and adjusted EPS guidance of $10.30 to $10.90 were reaffirmed.
- Full-year 2026 cash from operations is now expected at $700 million to $800 million.
- Tate & Lyle shareholders approved Ingredion's 595 pence all-cash offer on July 28, 2026; the acquisition is pending.
Read the filing on SEC.gov ↗
Jun 25, 4:18 PM ET
Ingredion entered a $1.475 billion senior unsecured delayed draw term loan agreement with JPMorgan Chase Bank as administrative agent, dated June 24, 2026. The loans can fund the cash consideration for its offer to buy Tate & Lyle PLC, the repayment of certain Tate & Lyle debt, and acquisition fees and costs. The new debt adds to Ingredion's borrowing, and the loan is subject to covenants on leverage and interest coverage.
- Facility totals $1,475,000,000: a $500,000,000 Tranche A-1 and a $975,000,000 Tranche B-1, maturing three and five years after funding, respectively.
- Loans amortize quarterly at 5% per year of outstanding principal and can be prepaid without premium or penalty.
- Covenants include a maximum leverage ratio of 3.5 to 1.0 and a minimum interest coverage ratio of 3.5 to 1.0.
- Commitments terminate automatically on February 2, 2028, and the $2,750,000,000 tranche B commitment under the June 8, 2026 bridge facility remains outstanding.
Read the filing on SEC.gov ↗
Jun 11, 4:15 PM ET
Ingredion's Board elected Kenneth Escoe, Executive Vice President of Specialty Products at Illinois Tool Works, as a director on June 7, 2026, effective July 1, 2026. The Board determined he is independent under NYSE standards, and he will receive standard non-management director compensation.
- Board elected Kenneth Escoe as a director on June 7, 2026; term begins July 1, 2026
- Board determined Mr. Escoe is independent under New York Stock Exchange standards
- Mr. Escoe, age 51, has been Executive Vice President of Specialty Products at Illinois Tool Works since 2020
- He will receive annual cash and equity retainers under the Company's standard non-management director arrangements
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
